drugset / Trial / NCT06570291

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

NCT06570291

Phase 3 Recruiting 520 enrolled Wuxi Cellular Biopharmaceutical Group Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy

Timeline

Start
2025-02-28
Primary completion
2026-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sodium Hyaluronate Other / unclassified Other
Subject mesenchymal stem cells Cell therapy Other

Indications